Hanna Gött
Hanna Gött has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Eberhard Uhl
Department of Neurosurgery, Justus-Liebig-University Gießen, Klinikstraße 33, 35392 Gießen, Germany
1 shared publication Hildegard Dohmen
Institute of Neuropathology, University Hospital Giessen, Giessen, Germany
1 shared publicationMalgorzata Kolodziej
Department of Neurosurgery, University Hospital Giessen, Giessen, Germany
1 shared publicationMarco Stein
Department of Neurosurgery, University Hospital Giessen, Giessen, Germany
1 shared publicationSilke Kiez
Department of Pediatric Hematooncology, University Hospital Regensburg, Regensburg, Germany
1 shared publication
Latest Publications
- Open Access
- 4 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8675
FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma
Oncogenic fusion genes have emerged as successful targets in several malignancies, such as chronic myeloid leukemia and lung cancer. Fusion of the fibroblast growth receptor 3 and the transforming acidic coiled coil containing protein—FGFR3-TACC3 fusion—is prevalent in 3–4% of human glioblastoma. The fusion protein leads to the constitutively activated kinase signaling of FGFR3 and thereby promotes cell proliferation and tumor progression. The subgroup of FGFR3-TACC3 fusion-positive glioblastomas presents with recurrent clinical and histomolecular characteristics, defining a distinctive subtype of IDH-wildtype glioblastoma. This review aims to provide an overview of the available literature on FGFR3-TACC3 fusions in glioblastoma and possible implications for actual clinical practice.
- 4 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8675
Open AccessFGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma
Oncogenic fusion genes have emerged as successful targets in several malignancies, such as chronic myeloid leukemia and lung cancer. Fusion of the fibroblast growth receptor 3 and the transforming acidic coiled coil containing protein—FGFR3-TACC3 fusion—is prevalent in 3–4% of human glioblastoma. The fusion protein leads to the constitutively activated kinase signaling of FGFR3 and thereby promotes cell proliferation and tumor progression. The subgroup of FGFR3-TACC3 fusion-positive glioblastomas presents with recurrent clinical and histomolecular characteristics, defining a distinctive subtype of IDH-wildtype glioblastoma. This review aims to provide an overview of the available literature on FGFR3-TACC3 fusions in glioblastoma and possible implications for actual clinical practice.
- Open Access
- 18 February 2022
- Published by Springer Nature in Child's Nervous System
- Vol. 38 (9) , 1791-1796
Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M — a case report
Since high grade gliomas are aggressive brain tumors, intensive search for new treatment options is ongoing. For adult patients with newly diagnosed (ndGBM) and recurrent glioblastoma (rGBM), low intensity intermediate frequency alternating electric fields, known as tumor treating fields (TTFields) have been established as a new treatment modality. Tumor treating fields significantly increase survival rates in combination with adjuvant temozolomide (TMZ) in adult and GBM patients. Here, we report about feasibility and safety of treatment on a pediatric patient with diffuse midline glioma who is receiving TTFields therapy in combination with temozolomide.
- 18 February 2022
- Published by Springer Nature in Child's Nervous System
- Vol. 38 (9) , 1791-1796
Open AccessTumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M — a case report
Since high grade gliomas are aggressive brain tumors, intensive search for new treatment options is ongoing. For adult patients with newly diagnosed (ndGBM) and recurrent glioblastoma (rGBM), low intensity intermediate frequency alternating electric fields, known as tumor treating fields (TTFields) have been established as a new treatment modality. Tumor treating fields significantly increase survival rates in combination with adjuvant temozolomide (TMZ) in adult and GBM patients. Here, we report about feasibility and safety of treatment on a pediatric patient with diffuse midline glioma who is receiving TTFields therapy in combination with temozolomide.